Remote Monitoring Compared With Glucose Sensors for Type 2 Diabetes
Compares remote monitoring and glucose sensors with usual care in adults with type 2 diabetes.
Key facts
- Who runs it
- Lawndale Christian Health Center
- Where
- Chicago, United StatesSee the site
- Trial code
- Registry title
- Using Remote Monitoring to Address Health Disparities in Type 2 Diabetes
- Status
- Enrolling by invitation
- People taking part
- 150 people, planned
- Started
- 1 Dec 2024
- Planned end
- 30 Sept 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Blood glucose monitor with Digital Platform and Health Coaching
- Continuous glucose monitor
- Usual Care
- Record updated
- 11 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who take insulin and whose blood sugar control is not on target (HbA1c 8.0% (64 mmol/mol) or higher).
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with an HbA1c of 8.0% (64 mmol/mol) or higher.
- Earlier treatment
- Must be using insulin. Must have an assigned primary care provider.
- Biomarker or test result
- HbA1c of 8.0% (64 mmol/mol) or higher.
Main reasons for not taking part
- Chronic kidney disease at Stage 4 or higher
- Pregnancy
- Serious mental illness or severe depression in the past 6 months
- No smartphone that can access internet services
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 18 years of age or older
- Have an assigned primary care provider
- Diagnosis of Type 2 diabetes
- Medication use is insulin
- HbA1c of 8.0% or higher
Who cannot take part
- Diagnosis of chronic kidney disease at Stage 4 or higher
- Diagnosis of behavioral health conditions including serious mental illness or severe depression in the past 6 months
- Diagnosis of pregnancy
- All participants must have a smartphone that is able to access internet services
Where in United States
- Lawndale Christian Health CenterChicago, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
Patient populations at community health centers, specifically Black or African American and Hispanic or Latino populations with Type 2 diabetes, experience significant health disparities. In particular, they have higher rates of diabetes-related complications and other related conditions such as myocardial infarction, cerebrovascular disease, kidney failure, blindness, neuropathy, and the risk of amputation. Diabetes affects 34 million adults in the US. Achieving a target HbA1c less than 8% can be challenging through diabetes management. Patients are able to monitor their blood glucose levels with devices such as blood glucose meters or continuous glucose monitors to facilitate diabetes management and glycemic control. Past studies have demonstrated that these devices are effective in engaging patients in the improvement of diabetes management. Current advancements in remote patient monitoring and self-monitoring have been observed to be effective in facilitating improvement in diabetes outcomes. However, the effectiveness and financial feasibility of these devices delivered in conjunction with automated patient engagement systems in remote patient monitoring programs is not well understood among underinsured, underserved, and vulnerable minority populations as they face a high-cost barrier particularly with continuous glucose monitors. To better address this gap in knowledge, this pilot study will compare and examine the effectiveness of these interventions on patient outcomes with Type 2 diabetes among populations in the West Side of Chicago. Study the comparative effectiveness among patients with uncontrolled Type 2 diabetes on insulin in an intervention group using remote patient monitoring and automated patient engagement system with blood glucose monitors to a group using a self-monitoring program with continuous glucose monitors and a usual care group receiving standard care. Conduct a feasibility analysis and financial impact of these programs among an underinsured and underserved population of Black/African Americans or Hispanic/Latinos with Type 2 diabetes.
The 3 groups in the trial
- Remote patient monitoring and automated patient engagement system with blood glucose monitorsTreatment being tested
Participants in this group will receive blood glucose monitors and will check their blood glucose daily with monitoring through a digital platform and provided health coaching.
Treatment: Blood glucose monitor with Digital Platform and Health Coaching
- Self-monitoring program with continuous glucose monitorsTreatment being tested
Participants in this group will receive continuous glucose monitors and will self monitor their blood glucose measurements with support by their care team.
Treatment: Continuous glucose monitor
- Usual care group receiving standard careExisting treatment, for comparison
Participants in this group will receive standard care for diabetes.
Treatment: Usual Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Trial Using Remote Monitoring With an Automated Patient Engagement System and a Self-Monitoring Program With Continuous Glucose Monitors to Address Health Disparities in Type 2 Diabetes
- Plain-language title
- Remote Monitoring Compared With Glucose Sensors for Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 August 2025